FABP4 and type 2 diabetes mellitus: Tuncman et al. provided genetic support for the involvement of A-FABP in atherosclerosis in humans, where a reduction in A-FABP activity generated a metabolically favorable phenotype29 while Furuhashi et al. showed that inhibiting A-FABP is effective against severe atherosclerosis and type 2 diabetes in mice30.